Background Lupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological ...
Objective Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that ...
Objective Macrophage activation syndrome (MAS), a subtype of secondary haemophagocytic lymphohistiocytosis (HLH), is a rare ...
Background Systemic lupus erythematosus (SLE) is about 10 times more common among women than men. This sex bias was previously attributed to sex hormones. However, while sex hormones are abnormal in ...
Background Litifilimab is a humanized IgG1 monoclonal antibody targeting BDCA2, a receptor predominantly expressed on plasmacytoid dendritic cells (pDCs). In Part A of the Phase 2 LILAC study ...
Background Immunoglobulin gamma-3 subclass, also called the immunoglobulin gamma 3 chain C (IGHG3), normally comprises 5%–8% of all IgG in humans. The salivary IGHG3 was increased in Korean patients ...
Background Abnormalities of type I interferon signaling and production can initiate lupus development. Disturbances of nucleic acid-sensing molecules triggered autoreactivity in lupus mouse models.
Vaccination prevents infectious diseases by inducing/enhancing protective immunity, potentially translating into a lower rate of invasive infections and hospital admissions. Patients with autoimmune ...
Lupus nephritis (LN) affects up to 40% of patients with systemic lupus erythematosus (SLE) and leads to end stage kidney disease (ESRD) in 17–33% after 10 years. 1 We have investigated a number of ...
A patient pathway is the patient experience from the first symptom through the initial referral for diagnosis, treatment and follow-up, and includes diverse aspects of disease management, such as ...
As a consequence of increased survival over the last decades, patients with systemic lupus erythematosus (SLE) and their partners have an increased wish for pregnancy. However, pregnancy in SLE is ...
Background/purpose Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) is one of the most commonly used disease activity indices in clinical practice and research but this index doesn ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback